Marksans Pharma Ltd Q2FY17
Consolidated Results Q2FY17: (Rs. in crore)
|EBITDA Margin (%)||3.5||[1,665]|
|Net Profit (adjusted)||0.48||[98.7]|
Marksans Pharma Ltd’s Q2FY17 consolidated numbers misses Bloomberg estimates. Revenue for the period came in 10.9% below estimate of Rs 210 cr. Also, reported net profit for the period came in 95.8% below the estimate of Rs 11 cr.
Revenue for the quarter declined by 26.8% yoy to Rs 187.13 cr. Drop in revenue was mainly on account of 43.6% dip to Rs 137.25 in revenues from Europe, UK business as compared to H1FY16.
EBITDA declined by 87.4% yoy to Rs 6.47 cr while EBITDA margins dipped 1,665 bps yoy to 3.5%. Fall is because of operating expenses remaining flat yoy even though there is fall in revenues of 26.8% yoy.
Net profit dropped by 98.66% yoy to Rs 0.48 cr. However, finance cost has decreased 63% yoy.
Marksans Pharma Ltd ended at Rs. 47.55, down by 1.5 points or 3.06% from its previous closing of Rs. 49.05 on the BSE.
The scrip opened at Rs. 49.1 and touched a high and low of Rs. 49.1 and Rs. 45.2 respectively. A total of 861325(NSE+BSE) shares were traded on the counter. The stock traded above its 50 DMA.
BSE 51.00 1.30 (2.62%)
NSE 51.00 1.25 (2.51%)
***Note: This is a NSE Chart